Date: 2018-01-03
Type of information: Nomination
Compound:
Company: Nicox (France)
Therapeutic area: Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 3, 2018, Nicox announced the appointment of Tomas Navratil, as vice president and head of development, effective January 1, 2018. In this newly-created position, Dr. Navratil will be responsible for leading all of Nicox’s non-clinical and clinical development activities. He will report to Michael Bergamini, executive vice president and chief scientific officer of Nicox. Dr. Navratil brings to Nicox a significant experience in the biotechnology industry and has been involved with the discovery and development of new chemical entities, novel medical devices, and biodegradable implant formulations focused on improving drug delivery, Phase 1-4 clinical programs, and regulatory submissions to FDA and the EMA. Prior to joining Nicox, he served as senior vice president of development at Envisia Therapeutics, a privately held biotechnology company focused on the development of novel ocular therapies. In this role, Dr. Navratil led development activities for a portfolio of extended release ophthalmic therapies targeting the indications of glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), and cataracts. Prior to Envisia Therapeutics, he was at Parion Sciences, where he served as executive director of clinical research and product development. Previously, Dr. Navratil held several director-level positions in drug discovery and clinical development at Inspire Pharmaceuticals, most recently as director, medical & scientific affairs. He has been awarded multiple patents and authored multiple publications on ocular and pulmonary drug delivery and product development. He received his B.S. and Ph.D. in Chemistry from the University of North Carolina at Chapel Hill, where he now serves on the Chemistry Department’s advisory board.
Financial terms:
Latest news:
Is general: Yes
